 | • レポートコード：MRC2-11QY07162 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、113ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は平滑筋肉腫治療薬のグローバル市場について調査・分析したレポートです。種類別（AL-3818、BGB-290、C-21、その他）市場規模、用途別（クリニック、病院、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別平滑筋肉腫治療薬の競争状況、市場シェア ・世界の平滑筋肉腫治療薬市場：種類別市場規模 2015年-2020年（AL-3818、BGB-290、C-21、その他） ・世界の平滑筋肉腫治療薬市場：種類別市場規模予測 2021年-2026年（AL-3818、BGB-290、C-21、その他） ・世界の平滑筋肉腫治療薬市場：用途別市場規模 2015年-2020年（クリニック、病院、その他） ・世界の平滑筋肉腫治療薬市場：用途別市場規模予測 2021年-2026年（クリニック、病院、その他） ・北米の平滑筋肉腫治療薬市場分析：米国、カナダ ・ヨーロッパの平滑筋肉腫治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの平滑筋肉腫治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の平滑筋肉腫治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの平滑筋肉腫治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Advenchen Laboratories, LLC、BeiGene, Ltd.、Cell Medica Limited、Karyopharm Therapeutics, Inc.、Merck & Co., Inc.、Mirati Therapeutics Inc.、Novartis AG、Vicore Pharma AB ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Market Analysis and Insights: Global Leiomyosarcoma Drug Market
The global Leiomyosarcoma Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Leiomyosarcoma Drug Scope and Market Size
Leiomyosarcoma Drug market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Leiomyosarcoma Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Leiomyosarcoma Drug market is segmented into
AL-3818
BGB-290
C-21
Others
Segment by Application, the Leiomyosarcoma Drug market is segmented into
Clinic
Hospital
Others
Regional and Country-level Analysis
The Leiomyosarcoma Drug market is analysed and market size information is provided by regions (countries).
The key regions covered in the Leiomyosarcoma Drug market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Leiomyosarcoma Drug Market Share Analysis
Leiomyosarcoma Drug market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Leiomyosarcoma Drug business, the date to enter into the Leiomyosarcoma Drug market, Leiomyosarcoma Drug product introduction, recent developments, etc.
The major vendors covered:
Advenchen Laboratories, LLC
BeiGene, Ltd.
Cell Medica Limited
Karyopharm Therapeutics, Inc.
Merck & Co., Inc.
Mirati Therapeutics Inc.
Novartis AG
Vicore Pharma AB
1 Study Coverage
1.1 Leiomyosarcoma Drug Product Introduction
1.2 Market Segments
1.3 Key Leiomyosarcoma Drug Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Leiomyosarcoma Drug Market Size Growth Rate by Type
1.4.2 AL-3818
1.4.3 BGB-290
1.4.4 C-21
1.4.5 Others
1.5 Market by Application
1.5.1 Global Leiomyosarcoma Drug Market Size Growth Rate by Application
1.5.2 Clinic
1.5.3 Hospital
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Leiomyosarcoma Drug Market Size, Estimates and Forecasts
2.1.1 Global Leiomyosarcoma Drug Revenue 2015-2026
2.1.2 Global Leiomyosarcoma Drug Sales 2015-2026
2.2 Global Leiomyosarcoma Drug, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Leiomyosarcoma Drug Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Leiomyosarcoma Drug Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Leiomyosarcoma Drug Competitor Landscape by Players
3.1 Leiomyosarcoma Drug Sales by Manufacturers
3.1.1 Leiomyosarcoma Drug Sales by Manufacturers (2015-2020)
3.1.2 Leiomyosarcoma Drug Sales Market Share by Manufacturers (2015-2020)
3.2 Leiomyosarcoma Drug Revenue by Manufacturers
3.2.1 Leiomyosarcoma Drug Revenue by Manufacturers (2015-2020)
3.2.2 Leiomyosarcoma Drug Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Leiomyosarcoma Drug Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Leiomyosarcoma Drug Revenue in 2019
3.2.5 Global Leiomyosarcoma Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Leiomyosarcoma Drug Price by Manufacturers
3.4 Leiomyosarcoma Drug Manufacturing Base Distribution, Product Types
3.4.1 Leiomyosarcoma Drug Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Leiomyosarcoma Drug Product Type
3.4.3 Date of International Manufacturers Enter into Leiomyosarcoma Drug Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Leiomyosarcoma Drug Market Size by Type (2015-2020)
4.1.1 Global Leiomyosarcoma Drug Sales by Type (2015-2020)
4.1.2 Global Leiomyosarcoma Drug Revenue by Type (2015-2020)
4.1.3 Leiomyosarcoma Drug Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Leiomyosarcoma Drug Market Size Forecast by Type (2021-2026)
4.2.1 Global Leiomyosarcoma Drug Sales Forecast by Type (2021-2026)
4.2.2 Global Leiomyosarcoma Drug Revenue Forecast by Type (2021-2026)
4.2.3 Leiomyosarcoma Drug Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Leiomyosarcoma Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Leiomyosarcoma Drug Market Size by Application (2015-2020)
5.1.1 Global Leiomyosarcoma Drug Sales by Application (2015-2020)
5.1.2 Global Leiomyosarcoma Drug Revenue by Application (2015-2020)
5.1.3 Leiomyosarcoma Drug Price by Application (2015-2020)
5.2 Leiomyosarcoma Drug Market Size Forecast by Application (2021-2026)
5.2.1 Global Leiomyosarcoma Drug Sales Forecast by Application (2021-2026)
5.2.2 Global Leiomyosarcoma Drug Revenue Forecast by Application (2021-2026)
5.2.3 Global Leiomyosarcoma Drug Price Forecast by Application (2021-2026)
6 North America
6.1 North America Leiomyosarcoma Drug by Country
6.1.1 North America Leiomyosarcoma Drug Sales by Country
6.1.2 North America Leiomyosarcoma Drug Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Leiomyosarcoma Drug Market Facts & Figures by Type
6.3 North America Leiomyosarcoma Drug Market Facts & Figures by Application
7 Europe
7.1 Europe Leiomyosarcoma Drug by Country
7.1.1 Europe Leiomyosarcoma Drug Sales by Country
7.1.2 Europe Leiomyosarcoma Drug Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Leiomyosarcoma Drug Market Facts & Figures by Type
7.3 Europe Leiomyosarcoma Drug Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Leiomyosarcoma Drug by Region
8.1.1 Asia Pacific Leiomyosarcoma Drug Sales by Region
8.1.2 Asia Pacific Leiomyosarcoma Drug Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Leiomyosarcoma Drug Market Facts & Figures by Type
8.3 Asia Pacific Leiomyosarcoma Drug Market Facts & Figures by Application
9 Latin America
9.1 Latin America Leiomyosarcoma Drug by Country
9.1.1 Latin America Leiomyosarcoma Drug Sales by Country
9.1.2 Latin America Leiomyosarcoma Drug Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Leiomyosarcoma Drug Market Facts & Figures by Type
9.3 Central & South America Leiomyosarcoma Drug Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Leiomyosarcoma Drug by Country
10.1.1 Middle East and Africa Leiomyosarcoma Drug Sales by Country
10.1.2 Middle East and Africa Leiomyosarcoma Drug Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Leiomyosarcoma Drug Market Facts & Figures by Type
10.3 Middle East and Africa Leiomyosarcoma Drug Market Facts & Figures by Application
11 Company Profiles
11.1 Advenchen Laboratories, LLC
11.1.1 Advenchen Laboratories, LLC Corporation Information
11.1.2 Advenchen Laboratories, LLC Description and Business Overview
11.1.3 Advenchen Laboratories, LLC Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Advenchen Laboratories, LLC Leiomyosarcoma Drug Products Offered
11.1.5 Advenchen Laboratories, LLC Related Developments
11.2 BeiGene, Ltd.
11.2.1 BeiGene, Ltd. Corporation Information
11.2.2 BeiGene, Ltd. Description and Business Overview
11.2.3 BeiGene, Ltd. Sales, Revenue and Gross Margin (2015-2020)
11.2.4 BeiGene, Ltd. Leiomyosarcoma Drug Products Offered
11.2.5 BeiGene, Ltd. Related Developments
11.3 Cell Medica Limited
11.3.1 Cell Medica Limited Corporation Information
11.3.2 Cell Medica Limited Description and Business Overview
11.3.3 Cell Medica Limited Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Cell Medica Limited Leiomyosarcoma Drug Products Offered
11.3.5 Cell Medica Limited Related Developments
11.4 Karyopharm Therapeutics, Inc.
11.4.1 Karyopharm Therapeutics, Inc. Corporation Information
11.4.2 Karyopharm Therapeutics, Inc. Description and Business Overview
11.4.3 Karyopharm Therapeutics, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Karyopharm Therapeutics, Inc. Leiomyosarcoma Drug Products Offered
11.4.5 Karyopharm Therapeutics, Inc. Related Developments
11.5 Merck & Co., Inc.
11.5.1 Merck & Co., Inc. Corporation Information
11.5.2 Merck & Co., Inc. Description and Business Overview
11.5.3 Merck & Co., Inc. Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Merck & Co., Inc. Leiomyosarcoma Drug Products Offered
11.5.5 Merck & Co., Inc. Related Developments
11.6 Mirati Therapeutics Inc.
11.6.1 Mirati Therapeutics Inc. Corporation Information
11.6.2 Mirati Therapeutics Inc. Description and Business Overview
11.6.3 Mirati Therapeutics Inc. Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Mirati Therapeutics Inc. Leiomyosarcoma Drug Products Offered
11.6.5 Mirati Therapeutics Inc. Related Developments
11.7 Novartis AG
11.7.1 Novartis AG Corporation Information
11.7.2 Novartis AG Description and Business Overview
11.7.3 Novartis AG Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Novartis AG Leiomyosarcoma Drug Products Offered
11.7.5 Novartis AG Related Developments
11.8 Vicore Pharma AB
11.8.1 Vicore Pharma AB Corporation Information
11.8.2 Vicore Pharma AB Description and Business Overview
11.8.3 Vicore Pharma AB Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Vicore Pharma AB Leiomyosarcoma Drug Products Offered
11.8.5 Vicore Pharma AB Related Developments
11.1 Advenchen Laboratories, LLC
11.1.1 Advenchen Laboratories, LLC Corporation Information
11.1.2 Advenchen Laboratories, LLC Description and Business Overview
11.1.3 Advenchen Laboratories, LLC Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Advenchen Laboratories, LLC Leiomyosarcoma Drug Products Offered
11.1.5 Advenchen Laboratories, LLC Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Leiomyosarcoma Drug Market Estimates and Projections by Region
12.1.1 Global Leiomyosarcoma Drug Sales Forecast by Regions 2021-2026
12.1.2 Global Leiomyosarcoma Drug Revenue Forecast by Regions 2021-2026
12.2 North America Leiomyosarcoma Drug Market Size Forecast (2021-2026)
12.2.1 North America: Leiomyosarcoma Drug Sales Forecast (2021-2026)
12.2.2 North America: Leiomyosarcoma Drug Revenue Forecast (2021-2026)
12.2.3 North America: Leiomyosarcoma Drug Market Size Forecast by Country (2021-2026)
12.3 Europe Leiomyosarcoma Drug Market Size Forecast (2021-2026)
12.3.1 Europe: Leiomyosarcoma Drug Sales Forecast (2021-2026)
12.3.2 Europe: Leiomyosarcoma Drug Revenue Forecast (2021-2026)
12.3.3 Europe: Leiomyosarcoma Drug Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Leiomyosarcoma Drug Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Leiomyosarcoma Drug Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Leiomyosarcoma Drug Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Leiomyosarcoma Drug Market Size Forecast by Region (2021-2026)
12.5 Latin America Leiomyosarcoma Drug Market Size Forecast (2021-2026)
12.5.1 Latin America: Leiomyosarcoma Drug Sales Forecast (2021-2026)
12.5.2 Latin America: Leiomyosarcoma Drug Revenue Forecast (2021-2026)
12.5.3 Latin America: Leiomyosarcoma Drug Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Leiomyosarcoma Drug Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Leiomyosarcoma Drug Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Leiomyosarcoma Drug Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Leiomyosarcoma Drug Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Leiomyosarcoma Drug Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Leiomyosarcoma Drug Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Leiomyosarcoma Drug Market Segments
Table 2. Ranking of Global Top Leiomyosarcoma Drug Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Leiomyosarcoma Drug Market Size Growth Rate by Type 2020-2026 (K Pcs) & (US$ Million)
Table 4. Major Manufacturers of AL-3818
Table 5. Major Manufacturers of BGB-290
Table 6. Major Manufacturers of C-21
Table 7. Major Manufacturers of Others
Table 8. Global Leiomyosarcoma Drug Market Size Growth Rate by Application 2020-2026 (K Pcs)
Table 9. Global Leiomyosarcoma Drug Market Size by Region (K Pcs) & (US$ Million): 2020 VS 2026
Table 10. Global Leiomyosarcoma Drug Sales by Regions 2015-2020 (K Pcs)
Table 11. Global Leiomyosarcoma Drug Sales Market Share by Regions (2015-2020)
Table 12. Global Leiomyosarcoma Drug Revenue by Regions 2015-2020 (US$ Million)
Table 13. Global Leiomyosarcoma Drug Sales by Manufacturers (2015-2020) (K Pcs)
Table 14. Global Leiomyosarcoma Drug Sales Share by Manufacturers (2015-2020)
Table 15. Global Leiomyosarcoma Drug Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 16. Global Leiomyosarcoma Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Leiomyosarcoma Drug as of 2019)
Table 17. Leiomyosarcoma Drug Revenue by Manufacturers (2015-2020) (US$ Million)
Table 18. Leiomyosarcoma Drug Revenue Share by Manufacturers (2015-2020)
Table 19. Key Manufacturers Leiomyosarcoma Drug Price (2015-2020) (USD/Pcs)
Table 20. Leiomyosarcoma Drug Manufacturers Manufacturing Base Distribution and Headquarters
Table 21. Manufacturers Leiomyosarcoma Drug Product Type
Table 22. Date of International Manufacturers Enter into Leiomyosarcoma Drug Market
Table 23. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 24. Global Leiomyosarcoma Drug Sales by Type (2015-2020) (K Pcs)
Table 25. Global Leiomyosarcoma Drug Sales Share by Type (2015-2020)
Table 26. Global Leiomyosarcoma Drug Revenue by Type (2015-2020) (US$ Million)
Table 27. Global Leiomyosarcoma Drug Revenue Share by Type (2015-2020)
Table 28. Leiomyosarcoma Drug Average Selling Price (ASP) by Type 2015-2020 (USD/Pcs)
Table 29. Global Leiomyosarcoma Drug Sales by Application (2015-2020) (K Pcs)
Table 30. Global Leiomyosarcoma Drug Sales Share by Application (2015-2020)
Table 31. North America Leiomyosarcoma Drug Sales by Country (2015-2020) (K Pcs)
Table 32. North America Leiomyosarcoma Drug Sales Market Share by Country (2015-2020)
Table 33. North America Leiomyosarcoma Drug Revenue by Country (2015-2020) (US$ Million)
Table 34. North America Leiomyosarcoma Drug Revenue Market Share by Country (2015-2020)
Table 35. North America Leiomyosarcoma Drug Sales by Type (2015-2020) (K Pcs)
Table 36. North America Leiomyosarcoma Drug Sales Market Share by Type (2015-2020)
Table 37. North America Leiomyosarcoma Drug Sales by Application (2015-2020) (K Pcs)
Table 38. North America Leiomyosarcoma Drug Sales Market Share by Application (2015-2020)
Table 39. Europe Leiomyosarcoma Drug Sales by Country (2015-2020) (K Pcs)
Table 40. Europe Leiomyosarcoma Drug Sales Market Share by Country (2015-2020)
Table 41. Europe Leiomyosarcoma Drug Revenue by Country (2015-2020) (US$ Million)
Table 42. Europe Leiomyosarcoma Drug Revenue Market Share by Country (2015-2020)
Table 43. Europe Leiomyosarcoma Drug Sales by Type (2015-2020) (K Pcs)
Table 44. Europe Leiomyosarcoma Drug Sales Market Share by Type (2015-2020)
Table 45. Europe Leiomyosarcoma Drug Sales by Application (2015-2020) (K Pcs)
Table 46. Europe Leiomyosarcoma Drug Sales Market Share by Application (2015-2020)
Table 47. Asia Pacific Leiomyosarcoma Drug Sales by Region (2015-2020) (K Pcs)
Table 48. Asia Pacific Leiomyosarcoma Drug Sales Market Share by Region (2015-2020)
Table 49. Asia Pacific Leiomyosarcoma Drug Revenue by Region (2015-2020) (US$ Million)
Table 50. Asia Pacific Leiomyosarcoma Drug Revenue Market Share by Region (2015-2020)
Table 51. Asia Pacific Leiomyosarcoma Drug Sales by Type (2015-2020) (K Pcs)
Table 52. Asia Pacific Leiomyosarcoma Drug Sales Market Share by Type (2015-2020)
Table 53. Asia Pacific Leiomyosarcoma Drug Sales by Application (2015-2020) (K Pcs)
Table 54. Asia Pacific Leiomyosarcoma Drug Sales Market Share by Application (2015-2020)
Table 55. Latin America Leiomyosarcoma Drug Sales by Country (2015-2020) (K Pcs)
Table 56. Latin America Leiomyosarcoma Drug Sales Market Share by Country (2015-2020)
Table 57. Latin Americaa Leiomyosarcoma Drug Revenue by Country (2015-2020) (US$ Million)
Table 58. Latin America Leiomyosarcoma Drug Revenue Market Share by Country (2015-2020)
Table 59. Latin America Leiomyosarcoma Drug Sales by Type (2015-2020) (K Pcs)
Table 60. Latin America Leiomyosarcoma Drug Sales Market Share by Type (2015-2020)
Table 61. Latin America Leiomyosarcoma Drug Sales by Application (2015-2020) (K Pcs)
Table 62. Latin America Leiomyosarcoma Drug Sales Market Share by Application (2015-2020)
Table 63. Middle East and Africa Leiomyosarcoma Drug Sales by Country (2015-2020) (K Pcs)
Table 64. Middle East and Africa Leiomyosarcoma Drug Sales Market Share by Country (2015-2020)
Table 65. Middle East and Africa Leiomyosarcoma Drug Revenue by Country (2015-2020) (US$ Million)
Table 66. Middle East and Africa Leiomyosarcoma Drug Revenue Market Share by Country (2015-2020)
Table 67. Middle East and Africa Leiomyosarcoma Drug Sales by Type (2015-2020) (K Pcs)
Table 68. Middle East and Africa Leiomyosarcoma Drug Sales Market Share by Type (2015-2020)
Table 69. Middle East and Africa Leiomyosarcoma Drug Sales by Application (2015-2020) (K Pcs)
Table 70. Middle East and Africa Leiomyosarcoma Drug Sales Market Share by Application (2015-2020)
Table 71. Advenchen Laboratories, LLC Corporation Information
Table 72. Advenchen Laboratories, LLC Description and Major Businesses
Table 73. Advenchen Laboratories, LLC Leiomyosarcoma Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 74. Advenchen Laboratories, LLC Product
Table 75. Advenchen Laboratories, LLC Recent Development
Table 76. BeiGene, Ltd. Corporation Information
Table 77. BeiGene, Ltd. Description and Major Businesses
Table 78. BeiGene, Ltd. Leiomyosarcoma Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 79. BeiGene, Ltd. Product
Table 80. BeiGene, Ltd. Recent Development
Table 81. Cell Medica Limited Corporation Information
Table 82. Cell Medica Limited Description and Major Businesses
Table 83. Cell Medica Limited Leiomyosarcoma Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 84. Cell Medica Limited Product
Table 85. Cell Medica Limited Recent Development
Table 86. Karyopharm Therapeutics, Inc. Corporation Information
Table 87. Karyopharm Therapeutics, Inc. Description and Major Businesses
Table 88. Karyopharm Therapeutics, Inc. Leiomyosarcoma Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 89. Karyopharm Therapeutics, Inc. Product
Table 90. Karyopharm Therapeutics, Inc. Recent Development
Table 91. Merck & Co., Inc. Corporation Information
Table 92. Merck & Co., Inc. Description and Major Businesses
Table 93. Merck & Co., Inc. Leiomyosarcoma Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 94. Merck & Co., Inc. Product
Table 95. Merck & Co., Inc. Recent Development
Table 96. Mirati Therapeutics Inc. Corporation Information
Table 97. Mirati Therapeutics Inc. Description and Major Businesses
Table 98. Mirati Therapeutics Inc. Leiomyosarcoma Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 99. Mirati Therapeutics Inc. Product
Table 100. Mirati Therapeutics Inc. Recent Development
Table 101. Novartis AG Corporation Information
Table 102. Novartis AG Description and Major Businesses
Table 103. Novartis AG Leiomyosarcoma Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 104. Novartis AG Product
Table 105. Novartis AG Recent Development
Table 106. Vicore Pharma AB Corporation Information
Table 107. Vicore Pharma AB Description and Major Businesses
Table 108. Vicore Pharma AB Leiomyosarcoma Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 109. Vicore Pharma AB Product
Table 110. Vicore Pharma AB Recent Development
Table 111. Global Leiomyosarcoma Drug Sales Forecast by Regions (2021-2026) (K Pcs)
Table 112. Global Leiomyosarcoma Drug Sales Market Share Forecast by Regions (2021-2026)
Table 113. Global Leiomyosarcoma Drug Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 114. Global Leiomyosarcoma Drug Revenue Market Share Forecast by Regions (2021-2026)
Table 115. North America: Leiomyosarcoma Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 116. North America: Leiomyosarcoma Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 117. Europe: Leiomyosarcoma Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 118. Europe: Leiomyosarcoma Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 119. Asia Pacific: Leiomyosarcoma Drug Sales Forecast by Region (2021-2026) (K Pcs)
Table 120. Asia Pacific: Leiomyosarcoma Drug Revenue Forecast by Region (2021-2026) (US$ Million)
Table 121. Latin America: Leiomyosarcoma Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 122. Latin America: Leiomyosarcoma Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 123. Middle East and Africa: Leiomyosarcoma Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 124. Middle East and Africa: Leiomyosarcoma Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 125. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 126. Key Challenges
Table 127. Market Risks
Table 128. Main Points Interviewed from Key Leiomyosarcoma Drug Players
Table 129. Leiomyosarcoma Drug Customers List
Table 130. Leiomyosarcoma Drug Distributors List
Table 131. Research Programs/Design for This Report
Table 132. Key Data Information from Secondary Sources
Table 133. Key Data Information from Primary Sources
List of Figures
Figure 1. Leiomyosarcoma Drug Product Picture
Figure 2. Global Leiomyosarcoma Drug Sales Market Share by Type in 2020 & 2026
Figure 3. AL-3818 Product Picture
Figure 4. BGB-290 Product Picture
Figure 5. C-21 Product Picture
Figure 6. Others Product Picture
Figure 7. Global Leiomyosarcoma Drug Sales Market Share by Application in 2020 & 2026
Figure 8. Clinic
Figure 9. Hospital
Figure 10. Others
Figure 11. Leiomyosarcoma Drug Report Years Considered
Figure 12. Global Leiomyosarcoma Drug Market Size 2015-2026 (US$ Million)
Figure 13. Global Leiomyosarcoma Drug Sales 2015-2026 (K Pcs)
Figure 14. Global Leiomyosarcoma Drug Market Size Market Share by Region: 2020 Versus 2026
Figure 15. Global Leiomyosarcoma Drug Sales Market Share by Region (2015-2020)
Figure 16. Global Leiomyosarcoma Drug Sales Market Share by Region in 2019
Figure 17. Global Leiomyosarcoma Drug Revenue Market Share by Region (2015-2020)
Figure 18. Global Leiomyosarcoma Drug Revenue Market Share by Region in 2019
Figure 19. Global Leiomyosarcoma Drug Sales Share by Manufacturer in 2019
Figure 20. The Top 10 and 5 Players Market Share by Leiomyosarcoma Drug Revenue in 2019
Figure 21. Leiomyosarcoma Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 22. Global Leiomyosarcoma Drug Sales Market Share by Type (2015-2020)
Figure 23. Global Leiomyosarcoma Drug Sales Market Share by Type in 2019
Figure 24. Global Leiomyosarcoma Drug Revenue Market Share by Type (2015-2020)
Figure 25. Global Leiomyosarcoma Drug Revenue Market Share by Type in 2019
Figure 26. Global Leiomyosarcoma Drug Market Share by Price Range (2015-2020)
Figure 27. Global Leiomyosarcoma Drug Sales Market Share by Application (2015-2020)
Figure 28. Global Leiomyosarcoma Drug Sales Market Share by Application in 2019
Figure 29. Global Leiomyosarcoma Drug Revenue Market Share by Application (2015-2020)
Figure 30. Global Leiomyosarcoma Drug Revenue Market Share by Application in 2019
Figure 31. North America Leiomyosarcoma Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 32. North America Leiomyosarcoma Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 33. North America Leiomyosarcoma Drug Sales Market Share by Country in 2019
Figure 34. North America Leiomyosarcoma Drug Revenue Market Share by Country in 2019
Figure 35. U.S. Leiomyosarcoma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 36. U.S. Leiomyosarcoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 37. Canada Leiomyosarcoma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 38. Canada Leiomyosarcoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 39. North America Leiomyosarcoma Drug Market Share by Type in 2019
Figure 40. North America Leiomyosarcoma Drug Market Share by Application in 2019
Figure 41. Europe Leiomyosarcoma Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 42. Europe Leiomyosarcoma Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 43. Europe Leiomyosarcoma Drug Sales Market Share by Country in 2019
Figure 44. Europe Leiomyosarcoma Drug Revenue Market Share by Country in 2019
Figure 45. Germany Leiomyosarcoma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 46. Germany Leiomyosarcoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 47. France Leiomyosarcoma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 48. France Leiomyosarcoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 49. U.K. Leiomyosarcoma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 50. U.K. Leiomyosarcoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 51. Italy Leiomyosarcoma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 52. Italy Leiomyosarcoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. Russia Leiomyosarcoma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 54. Russia Leiomyosarcoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. Europe Leiomyosarcoma Drug Market Share by Type in 2019
Figure 56. Europe Leiomyosarcoma Drug Market Share by Application in 2019
Figure 57. Asia Pacific Leiomyosarcoma Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 58. Asia Pacific Leiomyosarcoma Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 59. Asia Pacific Leiomyosarcoma Drug Sales Market Share by Region in 2019
Figure 60. Asia Pacific Leiomyosarcoma Drug Revenue Market Share by Region in 2019
Figure 61. China Leiomyosarcoma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 62. China Leiomyosarcoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 63. Japan Leiomyosarcoma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 64. Japan Leiomyosarcoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 65. South Korea Leiomyosarcoma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 66. South Korea Leiomyosarcoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 67. India Leiomyosarcoma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 68. India Leiomyosarcoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. Australia Leiomyosarcoma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 70. Australia Leiomyosarcoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. Taiwan Leiomyosarcoma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 72. Taiwan Leiomyosarcoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. Indonesia Leiomyosarcoma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 74. Indonesia Leiomyosarcoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Thailand Leiomyosarcoma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 76. Thailand Leiomyosarcoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Malaysia Leiomyosarcoma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 78. Malaysia Leiomyosarcoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Philippines Leiomyosarcoma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 80. Philippines Leiomyosarcoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Vietnam Leiomyosarcoma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 82. Vietnam Leiomyosarcoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 83. Asia Pacific Leiomyosarcoma Drug Market Share by Type in 2019
Figure 84. Asia Pacific Leiomyosarcoma Drug Market Share by Application in 2019
Figure 85. Latin America Leiomyosarcoma Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 86. Latin America Leiomyosarcoma Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 87. Latin America Leiomyosarcoma Drug Sales Market Share by Country in 2019
Figure 88. Latin America Leiomyosarcoma Drug Revenue Market Share by Country in 2019
Figure 89. Mexico Leiomyosarcoma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 90. Mexico Leiomyosarcoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 91. Brazil Leiomyosarcoma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 92. Brazil Leiomyosarcoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 93. Argentina Leiomyosarcoma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 94. Argentina Leiomyosarcoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 95. Latin America Leiomyosarcoma Drug Market Share by Type in 2019
Figure 96. Latin America Leiomyosarcoma Drug Market Share by Application in 2019
Figure 97. Middle East and Africa Leiomyosarcoma Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 98. Middle East and Africa Leiomyosarcoma Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 99. Middle East and Africa Leiomyosarcoma Drug Sales Market Share by Country in 2019
Figure 100. Middle East and Africa Leiomyosarcoma Drug Revenue Market Share by Country in 2019
Figure 101. Turkey Leiomyosarcoma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 102. Turkey Leiomyosarcoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 103. Saudi Arabia Leiomyosarcoma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 104. Saudi Arabia Leiomyosarcoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 105. U.A.E Leiomyosarcoma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 106. U.A.E Leiomyosarcoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 107. Middle East and Africa Leiomyosarcoma Drug Market Share by Type in 2019
Figure 108. Middle East and Africa Leiomyosarcoma Drug Market Share by Application in 2019
Figure 109. North America Leiomyosarcoma Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 110. North America Leiomyosarcoma Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 111. Europe Leiomyosarcoma Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 112. Europe Leiomyosarcoma Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 113. Asia Pacific Leiomyosarcoma Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 114. Asia Pacific Leiomyosarcoma Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 115. Latin America Leiomyosarcoma Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 116. Latin America Leiomyosarcoma Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 117. Middle East and Africa Leiomyosarcoma Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 118. Middle East and Africa Leiomyosarcoma Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 119. Porter's Five Forces Analysis
Figure 120. Channels of Distribution
Figure 121. Distributors Profiles
Figure 122. Bottom-up and Top-down Approaches for This Report
Figure 123. Data Triangulation
Figure 124. Key Executives Interviewed
小売薬の世界市場（～2026年） A drug is any substance (other than food that provides nutritional support) that, when inhaled, injected, smoked, consumed, absorbed via a patch on the skin, or dissolved under the tongue causes a temporary physiological (and often psychological) change in the body. Increasing industry share of Asia…- 大麻薬の世界市場（～2026年） Drugs with chemicals taken directly from the marijuana plant，or with synthetic versions of chemicals naturally found in marijuana. Market Analysis and Insights: Global Cannabis Drug Market The global Cannabis Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020,…
- 乱用薬物検査サービスの世界市場（～2026年） Drug of Abuse Testing Services is the use of testing services to avoid the negative effects of drug abuse, to reduce the accidents. In addition to rise in number of substance abusers and increase in number of government initiatives to avoid ill effects of substance abuse at workplace & reduce number…
- 薬物スクリーニング検査サービスの世界市場（～2026年） Market Analysis and Insights: Global Drug Screening Laboratory Service Market The global Drug Screening Laboratory Service market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high da…
- 子宮内膜ポリープ治療薬の世界市場（～2026年） Uterine polyps are common gynecological diseases. Broadly speaking, it refers to all tumors attached to the uterine wall by slender pedicle. Mostly benign. Market Analysis and Insights: Global Uterine Polyps Drug Market The global Uterine Polyps Drug market size is projected to reach US$ XX million …